Publications by authors named "N Latysheva"
Background: A high level of plasma coagulation factor (F)VIII is an established and likely causal risk factor for venous thromboembolism (VTE). Procoagulant phospholipids (PPLs) facilitate FVIII activity in coagulation.
Objectives: To assess the association between plasma levels of FVIII and risk of future VTE according to PPL clotting time (PPL), an inverse surrogate measure of plasma PPL activity.
Background: Scientific and clinical interest in extracellular vesicles (EVs) is growing. EVs that expose tissue factor (TF) bind factor VII/VIIa and can trigger coagulation. Highly procoagulant TF-exposing EVs are detectable in the circulation in various diseases, such as sepsis, COVID-19, or cancer.
View Article and Find Full Text PDFArticle Synopsis
- Small molecule CGRP receptor antagonists, known as gepants, emerged as a potential treatment for migraines between 2004 and 2011, but initial development faced challenges like oral availability and liver toxicity concerns.
- The newer generation of gepants, including ubrogepant and rimegepant, has recently been approved for treating acute migraines, following a 15-year gap in development.
- The chapter reviews the effectiveness, safety, and tolerability of gepants, as well as their limitations and future potential in migraine treatment.
Background: Extracellular vesicles (EVs), in particular those derived from activated platelets, are associated with a risk of future venous thromboembolism.
Objectives: To study the biomolecular profile and function characteristics of EVs from control (unstimulated) and activated platelets.
Methods: Biomolecular profiling of single or very few (1-4) platelet-EVs (control/stimulated) was performed by Raman tweezers microspectroscopy.
Objective: To access the effect of Relatox, the first Russian botulinum toxin type A, in patients with chronic migraine (CM) and medication overuse (MO).
Material And Methods: In phase IIIb single-blind randomized multicenter active-controlled parallel-group study, patients with CM were randomized to once intramuscular injections of Relatox (101) or onabotulinumtoxin A injections - Botox (108). This subgroup analysis evaluated the percentage of patients who transition from medication overuse to non overuse status from baseline; mean changes in the number of headache days, migraine headache days, acute headache medication intakes days, headache intensity, proportion of patients who had a ≥50% reduction in headache days, proportion of the patients with severe (≥60) Headache Impact Test-6 score and with a severe (≥21) MIDAS score in a 28-day periods in each treatment among patients with baseline acute medication overuse via repeated measures.